Zura Bio (ZURA)
Nasdaq Market Open
Zura Bio Limited is a clinical-stage biotechnology company focused on immune-mediated and inflammatory diseases where existing treatments often leave patients with persistent symptoms, relapses, or limited long-term control. The company’s strategy is built around acquiring and developing biologic drug candidates that act on validated immune pathways, with the goal of advancing therapies for serious chronic conditions that have significant unmet medical need.
Its pipeline includes three in-licensed clinical-stage assets. Tibulizumab, also known as ZB-106, is designed as a bispecific antibody that targets both IL-17A and BAFF, two pathways associated with inflammation and autoimmunity. Crebankitug, or ZB-168, is an IgG1 monoclonal antibody aimed at the IL-7 receptor, a target involved in T-cell biology and immune activation. Torudokimab, or ZB-880, is an IgG4 monoclonal antibody directed at IL-33, a cytokine linked to type 2 inflammation and tissue injury responses.
As a development-stage company, Zura Bio does not primarily compete through commercial sales. Its value is tied to clinical execution, regulatory progress, trial data, intellectual property, and the ability to identify indications where its candidates may offer meaningful differentiation. The company operates in a competitive biotechnology market that includes large pharmaceutical firms and specialist immunology developers. For investors, ZURA represents exposure to a concentrated portfolio of antibody-based therapies targeting biologically complex diseases, with the opportunities and risks typical of clinical-stage drug development.
Last updated
- Market Cap
- $512,037,657
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- $286,443,657
- Sector
- Materials
- Industry
- Biological Products, Except Diagnostic Substances
- Address
- 4225 EXECUTIVE SQUARE, LA JOLLA, CA, 92037
Tenaya Therapeutics Names Eric Hyllengren CFO Ahead Of Higa Retirement
UniFirst, Elastic NV, and More Stocks See Action From Activist Investors
December 2025's Top Penny Stocks With Promising Potential
Bullish Outlook on Zura Bio Limited (ZURA) Amid Tibulizumab Phase 2 Clinical Trial Progress
Zura Bio And 2 Other Promising Penny Stocks For Your Watchlist
INBX Soars 81% Post-Study; FEMY, CING, CYH Pop After Hours
Hidradenitis Suppurativa Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 24+ Companies and 26+ Therapies | DelveInsight
Noteworthy Thursday Option Activity: AKRO, DHI, AFRM
September 2025's Promising Penny Stocks Revealed
Spotlight On 3 Promising Penny Stocks With Over $60M Market Cap
Oppenheimer lowers Zura Bio stock price target to $16 on clinical updates
3 Penny Stocks With Market Caps Over $70M Worth Watching
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- $512,037,657
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- $286,443,657
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 2.36
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -3.52
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- -1.12
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -$72,752,000
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -48.93%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -46.42%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 19.33
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 19.33
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 19.21
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- $1,519,821
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 5.39
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Cost of revenue | 0 | 0 | 0 | 0 | 0 |
| Operating income | -25.5M | -18.41M | -19.52M | -18.06M | -19.25M |
| EBITDA | -25.48M | -18.4M | -19.51M | -18.05M | -19.25M |
| Net income | -24.22M | -45.88M | -20.04M | -15.99M | -17.44M |
| Other operating expenses | 0 | 0 | 0 | 0 | 0 |
| Total operating expenses | 25.5M | 18.41M | 19.52M | 18.06M | 19.25M |
| Basic EPS | -0.22 | -0.49 | -0.21 | -0.17 | -0.19 |
| Diluted EPS | -0.22 | -0.49 | -0.21 | -0.17 | -0.19 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 228.64M | 113.95M | 143.94M | 157.81M | 172.5M |
| Total liabilities | 11.75M | 12.41M | 25.49M | 18.7M | 21.09M |
| Total equity | 216.9M | 101.54M | 109.78M | 127.45M | 139.74M |
| Cash & equivalents | 225.59M | 109.41M | 139.02M | 154.49M | 170.57M |
| Current assets | 227M | 112.31M | 142.29M | 156.99M | 171.69M |
| Current liabilities | 11.75M | 12.41M | 25.49M | 18.7M | 21.09M |
| Accounts payable | 11.75M | 12.41M | 25.49M | 18.7M | 21.09M |
| Receivables | 0 | 0 | 0 | 0 | 0 |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -18.92M | -22.28M | -15.44M | -16.03M | -11.06M |
| Investing cash flow | -13K | -17K | -32K | -15K | -49K |
| Financing cash flow | 135.12M | -7.32M | 3K | -34K | 5.18M |
| Change in cash | 116.19M | -29.61M | -15.47M | -16.08M | -5.93M |
| Net income | -24.22M | -17.18M | -18.04M | -15.99M | -17.44M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 8-K — Zura Bio Ltd | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Zura Bio Ltd | View Filing | |
| edgar index | 4 — Zura Bio Ltd | View Filing | |
| edgar index | 4 — Zura Bio Ltd | View Filing | |
| edgar index | 4 — Zura Bio Ltd | View Filing | |
| edgar index | 4 — Zura Bio Ltd | View Filing | |
| edgar index | 4 — Zura Bio Ltd | View Filing | |
| edgar index | 4 — Zura Bio Ltd | View Filing | |
| edgar index | 3 — Zura Bio Ltd | View Filing | |
| form 3 | Form 3 — Mathew Marlyn Teresa | View Filing | |
| form 3 | Form 3 — Mathew Marlyn Teresa | View Filing | |
| form 3 | Form 3 — Mathew Marlyn Teresa | View Filing | |
| form 3 | Form 3 — Mathew Marlyn Teresa | View Filing | |
| form 3 | Form 3 — Mathew Marlyn Teresa | View Filing | |
| form 3 | Form 3 — Mathew Marlyn Teresa | View Filing | |
| edgar index | 8-K — Zura Bio Ltd | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Munshi Amit | View Filing | |
| form 4 | Form 4 — Jarrett Jennifer | View Filing | |
| form 4 | Form 4 — Becker Daniel J. | View Filing | |
| form 4 | Form 4 — Eisner Mark | View Filing | |
| form 4 | Form 4 — Schoch Steven J | View Filing | |
| form 4 | Form 4 — Thiara Parvinder | View Filing | |
| form 4 | Form 4 — Nirula Ajay | View Filing | |
| edgar index | 8-K — Zura Bio Ltd | View Filing | |
| edgar index | DEFA14A — Zura Bio Ltd | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — Zura Bio Ltd | View Filing | |
| edgar index | SCHEDULE 13G/A — Zura Bio Ltd | View Filing | |
| edgar index | SCHEDULE 13G/A — Zura Bio Ltd | View Filing | |
| edgar index | 10-Q — Zura Bio Ltd | View Filing | |
| edgar index | 8-K — Zura Bio Ltd | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — Zura Bio Ltd | View Filing | |
| edgar index | DEF 14A — Zura Bio Ltd | View Filing | |
| edgar index | ARS — Zura Bio Ltd | View Filing | |
| edgar index | 8-K — Zura Bio Ltd | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Zura Bio Ltd | View Filing | |
| edgar index | 4 — Zura Bio Ltd | View Filing | |
| edgar index | 4 — Zura Bio Ltd | View Filing | |
| edgar index | 4 — Zura Bio Ltd | View Filing | |
| edgar index | 4 — Zura Bio Ltd | View Filing | |
| form 4 | Form 4 — Kulkarni Sandeep Chidambar | View Filing | |
| form 4 | Form 4 — Davis Kim | View Filing | |
| form 4 | Form 4 — Whale Gary | View Filing | |
| form 4 | Form 4 — Hyllengren Eric J | View Filing | |
| form 4 | Form 4 — Nistala Kiran | View Filing | |
| edgar index | 8-K — Zura Bio Ltd | View Filing | |
| edgar index | 10-K — Zura Bio Ltd | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 8-K — Zura Bio Ltd | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Zura Bio Ltd | View Filing | |
| edgar index | 3 — Zura Bio Ltd | View Filing | |
| edgar index | 4 — Zura Bio Ltd | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13D/A — Zura Bio Ltd | View Filing | |
| edgar index | 4 — Zura Bio Ltd | View Filing | |
| edgar index | 8-K — Zura Bio Ltd | View Filing | |
| edgar index | 8-K/A — Zura Bio Ltd | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — AI Biotechnology LLC | View Filing | |
| form 4 | Form 4 — Access Industries Holdings LLC | View Filing | |
| form 4 | Form 4 — ACCESS INDUSTRIES MANAGEMENT, LLC | View Filing | |
| form 4 | Form 4 — Blavatnik Len | View Filing | |
| edgar index | 424B5 — Zura Bio Ltd | View Filing | |
| edgar index | 424B5 — Zura Bio Ltd | View Filing | |
| edgar index | 3 — Zura Bio Ltd | View Filing | |
| edgar index | 4 — Zura Bio Ltd | View Filing | |
| edgar index | 8-K — Zura Bio Ltd | View Filing |
- Trusted by 1M+ investors
- Global coverage
- Real-time market data
- Independent & unbiased
Join thousands making smarter investment decisions.
Get started for free